Cannabis and psychometrically-defined schizotypy: Use, problems and treatment considerations

Journal of Psychiatric Research

Volumn 45, Issue 4, 2011, Pages 548-554

  Cohen, Alex S ^a   Buckner, Julia D ^a   Najolia, Gina M ^a   Stewart, Diana W ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Cannabis; Disorganization; Functioning; Marijuana; Negative; Positive; Risk; Schizophrenia; Schizotypy

Indexed keywords

CANNABIS;

ADULT; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOMETRY; PSYCHOSOCIAL DISORDER; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; FEMALE; HUMANS; INCIDENCE; MALE; MARIJUANA ABUSE; PSYCHOMETRICS; SCHIZOTYPAL PERSONALITY DISORDER; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79952621488     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.08.013     Document Type: Article

References (59)

1. Aarons G.A., Brown S.A., Stice E., Coe M.T. Psychometric evaluation of the marijuana and stimulant effect expectancy questionnaires for adolescents. Addictive Behaviors 2001, 26:219-236.
2. Administration, S.A.and M.H.S Results from the 2005 National Survey on Drug Use and Health: National Findings. Office of Applied Studies, NSDUH Series H-30 2006, Rockville, MD.
3. Agosti V., Nunes E., Levin F. Rates of psychiatric comorbidity among U.S. residents with lifetime cannabis dependence. American Journal of Drug and Alcohol Abuse 2002, 28:643-652.
4. Arendt M., Mortensen P.B., Rosenberg R., Pedersen C.B., Waltoft B.L. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Archives of General Psychiatry 2008, 65:1269-1274.
5. Arseneault L., Cannon M., Witton J., Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 2004, 184:110-117.
6. Bailey E.L., Swallow B.L. The relationship between cannabis use and schizotypal symptoms. European Psychiatry 2004, 19:113-114.
7. Barkus E., Lewis S. Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychological Medicine 2008, 38:1267-1276.
8. Bellack A.S., Bennett M.E., Gearon J.S., Brown C.H., Yang Y. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness. Archives of General Psychiatry 2006, 63:426-432.
9. Buckner J.D., Bonn-Miller M.O., Zvolensky M.J., Schmidt N.B. Marijuana use motives and social anxiety among marijuana-using young adults. Addictive Behaviors 2007, 32:2238-2252.
10. Buckner J.D., Ecker A.H., Cohen A.S. Mental health problems and interest in marijuana treatment among marijuana-using college students. Addictive Behaviors 2010, 35(9):826-833.
11. Buckner J.D., Mallott M.A., Schmidt N.B., Taylor J. Peer influence and gender differences in problematic cannabis use among individuals with social anxiety. Journal of Anxiety Disorders 2006, 20:1087-1102.
12. Buckner J.D., Schmidt N.B. Marijuana effect expectancies: relations to social anxiety and marijuana use problems. Addictive Behaviors 2008, 33:1477-1483.
13. Buckner J.D., Schmidt N.B., Bobadilla L., Taylor J. Social anxiety and problematic cannabis use: evaluating the moderating role of stress reactivity and perceived coping. Behavior Research and Therapy 2006, 44:1007-1015.
14. Buckner J.D., Schmidt N.B., Lang A.R., Small J.W., Schlauch R.C., Lewinsohn P.M. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. Journal of Psychiatric Research 2008, 42:230-239.
15. Caspari D. Cannabis and schizophrenia: results of a follow-up study. European Archives of Psychiatry and Clinical Neuroscience 1999, 249:45-49.
16. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biological Psychiatry 2005, 57:1117-1127.
17. Chapman LJC, Jean P. 1976. The Infrequency Scale (Unpublished Test).
18. Cohen A.S., Leung W.W., Saperstein A.M., Blanchard J.J. Neuropsychological functioning and social anhedonia: results from a community high-risk study. Schizophrenia Research 2006, 85:132-141.
19. Cohen A.S., Matthews R. Primary and secondary negative schizotypal traits in a large non-clinical sample. Personality and Individual Differences 2010, 49(5):419-424.
20. Cohen AS, Matthews R, Najolia GM, Brown LA. A Psychometrically-sound and sensitive brief measure of schizotypy: improving the SPQ-B. Journal of Personality Disorders. in press-b.
21. Compton M.T., Chien V.H., Bollini A.M. Associations between past alcohol, cannabis, and cocaine use and current schizotypy among first-degree relatives of patients with schizophrenia and non-psychiatric controls. Psychiatric Quarterly 2009, 80:143-154.
22. Compton M.T., Goulding S.M., Walker E.F. Cannabis use, first-episode psychosis, and schizotypy: a summary and synthesis of recent literature. Current Psychiatry Reviews 2007, 3:161-171.
23. Cornblatt B.A., Lencz T., Kane J.M. Treatment of the schizoporenia prodome: it is presently ethical?. Schizophrenia Research 2001, 51:31-38.
24. Cunningham J. Is level of interest among cannabis users in self-help materials and other services aimed at reducing problem use?. Addiction 2005, 100:561-562.
25. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry 2005, 57:594-608.
26. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research 1999, 35:s93-s100.
27. Dumas P., Soaud M., Bouafia S.B., Gutknecht C., Ecochard R., Dalacry J., et al. Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Research 2002, 109:27-35.
28. Earleywine M. Schizotypy, marijuana, and differential item functioning. Human Psychopharmacology: Clinical and Experimental 2006, 21:455-461.
29. Esterberg M.L., Goulding S.M., McClure-Tone E.B., Compton M.T. Schizotypy and nicotine, alcohol, and cannabis use in a non-psychiatric sample. Addictive Behaviors 2009, 34:374-379.
30. Green B., Kavanagh D.J., Young R.M.C.D. Reasons for cannabis use in men with and without psychosis. Drug and Alcohol Review 2004, 23:445-453.
31. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. American Journal of Psychiatry 1996, 153:321-330.
32. Hall W., Degenhardt L., Teesson M. Cannabis use and psychotic disorders: an update. Drug and Alcohol Review 2004, 23:433-443.
33. Hayatbakhsh M.R., Najman J.M., Jamrozik K., Mamun A.A., Alati R., Bor W. Cannabis and anxiety and depression in young adults: a large prospective study. Journal of the American Academy of Child Psychiatry 2007, 46:408-417.
34. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the Future National Survey Results on Drug Use 1975-2007 2007, National Institutes of Health & U.S. Department of Health and Human Services, Bethesda, MD.
35. Kilmer J.R., Walker D.D., Lee C.M., Palmer R.S., Mallett K.A., Fabiano P., et al. Misperceptions of college student marijuana use: implications for prevention. Journal of Studies on Alcohol 2006, 67:277-281.
36. Kirkpatrick B., Amador X.F., Flaum M., Yale S.A., Gorman J.M., Carpenter W.T., et al. The deficit syndrome in the DSM-IV field trial: I. Alcohol and other drug abuse. Schizophrenia Research 1996, 20:69-77.
37. Lenzenweger M.F., Korfine L. Confirming the latent structure and base rate of schizotypy: a taxometric analysis. Journal of Abnormal Psychology 1992, 101:567-571.
38. Lewandowski K.E., Barrantes-Vidal N., Nelson-Gray R.O., Clancy C., Kepley H.O., Kwapil T.R. Anxiety and depression symptoms in psychometrically identified schizotypy. Schizophrenia Research 2006, 83:225-235.
39. Mass R., Bardong C., Kindl K., Dahme B. Relationship between cannabis use, schizotypal traits, and cognitive function in healthy subjects. Psychopathology 2001, 34:209-214.
40. Meehl P. Schizotaxia, schizotypy, schizophrenia. American Psychologist 1962, 17:827-838.
41. Miller P., Lawrie S.M., Hodges A., Clafferty R., Cosway R., Johnstone E.C. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Social Psychiatry and Psychiatric Epidemiology 2001, 36:338-342.
42. Miller W.R., Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behaviour 1991, Guilford Press, New York.
43. Morrison A.P., French P., Parker S., Roberts M., Stevens H., Bentall R.P., et al. Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophrenia Bulletin 2007, 33:682-687.
44. Morrison P.D., Zois V., McKeown D.A., Lee T.D., Holt D.W., Powell J.F., et al. The acute effects of synthetic intravenous delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychological Medicine 2009, 39:1607-1616.
45. Negrete J.C., Knapp W.P., Douglas D.E., Smith W.B. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychological Medicine 1986, 16:515-520.
46. Nunn J.A., Rizza F., Peters E.R. The incidence of schizotypy among cannabis and alcohol users. Journal of Nervous and Mental Disease 2001, 189:741-748.
47. Potvin S.P., Sepehry A.A., Stip E. A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychological Medicine 2006, 36:431-440.
48. Prochaska J.O., DiClemente C.C. Trans-theoretical therapy-toward a more integrative model of change. Psychotherapy: Theory, Research and Practice 1982, 19:276-288.
49. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophrenia Bulletin 1991, 17:555-564.
50. Reilly D., Didcott P., Swift W., Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction 1998, 93:837-846.
51. Schaub M., Fanghaenel K., Stohler R. Reasons for cannabis use: patients with schizophrenia versus matched healthy controls. Australian and New Zealand Journal of Psychiatry 2008, 42:1060-1065.
52. Schiffman J., Nakamura B., Earleywine M., LaBrie J. Symptoms of schizotypy precede cannabis use. Psychiatry Research 2005, 134:37-42.
53. Skosnik P.D., Krishnan G.P., Aydt E.E., Kuhlenshmidt H.A., O'Donnell B.F. Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. American Journal of Psychiatry 2006, 163:1798-1805.
54. Skosnik P.D., Spatz-Glenn L., Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophrenia Research 2001, 48:83-92.
55. Stephens R.S., Roffman R.A., Curtin L. Comparison of extended versus brief treatments for marijuana use. Journal of Consulting and Clinical Psychology 2000, 68:898-908.
56. Thomas H. A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence 1996, 42:201-207.
57. Walker E.F., Cornblatt B.A., Addington J., Cadenhead K.S., Cannon T.D., McGlashan T.H., et al. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American prodrome longitudinal sample. Schizophrenia Research 2009, 115:50-57.
58. Woods S.W., Breier A., Zipursky R.B., Perkins D.O., Addington J., Miller T.J., et al. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry 2003, 54:453-464.
59. Wuthrich V., Bates T.C. Reliability and validity of two likert versions of the schizotypal personality questionnaire (SPQ). Journal of Personality and Individual Differences 2005, 38:1543-1548.